Precision Medicine Market Poised To Grow At 11.5% By 2030

The global precision medicine market size reached USD 73.49 billion in 2022 and is projected to hit USD 175.64 billion by 2030 It is poised to grow at a CAGR of 11.5% from 2022 to 2030.

Table of Contents

Key Takeaway:

The North America market has captured 43% of the total revenue share in 2021.
By technology, the companion diagnostics segment is growing at a CAGR of 13.2% between 2022 to 2030.
By application, the oncology segment has contributed highest revenue share in 2021.
The CNS application segment has accounted 15% of the revenue share in 2021.
By end user, the hospital segment has dominated the market with revenue share of 53% in 2021.
The diagnostic centers end user segment is expanding at a CAGR of 13.3% from 2022 to 2030.

Precision medicine is an emerging approach of treatment and prevention of disease that takes into account the individual variability in environment, genes, and lifestyle for each person. This approach allows researchers and doctors to predict more precisely that which treatment and prevention strategies for a particular disease will work on the specified groups of people.

Although the term “precision medicine” is currently new to the consumers, the concept has been a part of healthcare industry for many years. For instance, a person who requires a blood transfusion is not given blood from any random donor; instead, the blood type of donor is matched with the recipient prior transfusion to reduce the risk of complications. Although examples can be found in various areas of medicine, the role of precision medicine in everyday healthcare is relatively limited. Researchers are significantly working to expand this approach in many areas of healthcare and health in the coming years.

Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1085

Growth Factors

The advent of precision medicine has significantly brought a paradigm shift in the drug delivery and diagnosis of the disease. The proliferation of sequencing methodologies, particularly Next Generation Sequencing (NGS), due to the increasing cost of sequencing and development of the Human Genome Project in the field of genomics is predicted to drive the market. NGS technology provides the data related to the patient’s genetic makeup along with response of drugs on the patient, thereby raising the development of precision medicine for the treatment of diseases. Moreover, NGS combined with Companion Diagnostics (CDx) is analyzed to play a significant role in the advancement of personalized therapeutics and diagnostics over the forecast period. Apart from the benefits offered by the precision medicine, they are highly expensive due to the application of high-end computational methods to examine individual genes projected to hinder the market growth.

Report Scope of the Precision Medicine Market

Report Coverage	Details
Market Size	USD 175.64 Billion by 2030
Growth Rate	CAGR of 11.5% from 2022 to 2030
Largest Market	North America
Fastest Growing Market	Asia Pacific
Base Year	2021
Forecast Period	2022 to 2030
Segments Covered	Technology, Application, End User, Sequencing Technology, Product, Route of Administration, Drugs, Region

Regional Snapshots

North America dominated the global precision medicine market with revenue share of nearly 40% in 2019 and expected to grow at an escalating pace during the forecast period. Technological advancement along with the presence of major players in the region contributes significantly towards the growth of the region. However, the Asia Pacific seeks to be the most opportunistic region in the precision medicine market owing to increasing cases of cancer and other diseases along with the health awareness among people.

Report Highlights

In 2019, North America captured more than 40% of the overall market value share in 2019 and projected to maintain its position in the coming years. Increasing prevalence of cancer along with the presence of key market players in the region expected to be the key factors contributing for the market growth in the region. Furthermore, demand for precision medicine is mainly driven by favorable government initiatives and rising investment for developing novel solutions for effective disease management.
The Asia Pacific seeks lucrative growth over the forecast period due to low cost clinical trials of newly developed diagnostic products and precision medicine. Furthermore, rising disposable income and rising economy in the developing nations such as India expected to boost the demand of precision medicines in the region.
By technology, drug discovery registered considerable growth in the recent past and expect to lead the overall market revenue in 2019. Advancement in pharmacogenomics expected to pave the way for significant growth of the drug discovery in the precision medicine.
Oncology application led the global precision medicine market with significant revenue share in 2019 and analyzed to grow at a prominent rate during the forecast period. Increasing prevalence of cancer across the globe expected to flourish the demand for precision medicine for effective therapeutic approach.
Based on end-use, pharmaceutical companies dominated the global precision medicine market with prominent revenue share contribution in the year 2019. The growth is mainly attributed to the availability of advanced and innovative techniques including next generation sequencing for identifying the drug related genetic alterations. In addition, major market participants in the precision medicine industry are involved in various investment programs that further escalate the market growth.

Report Highlights

In 2019, North America captured more than 40% of the overall market value share in 2019 and projected to maintain its position in the coming years. Increasing prevalence of cancer along with the presence of key market players in the region expected to be the key factors contributing for the market growth in the region. Furthermore, demand for precision medicine is mainly driven by favorable government initiatives and rising investment for developing novel solutions for effective disease management.
The Asia Pacific seeks lucrative growth over the forecast period due to low cost clinical trials of newly developed diagnostic products and precision medicine. Furthermore, rising disposable income and rising economy in the developing nations such as India expected to boost the demand of precision medicines in the region.
By technology, drug discovery registered considerable growth in the recent past and expect to lead the overall market revenue in 2019. Advancement in pharmacogenomics expected to pave the way for significant growth of the drug discovery in the precision medicine.
Oncology application led the global precision medicine market with significant revenue share in 2019 and analyzed to grow at a prominent rate during the forecast period. Increasing prevalence of cancer across the globe expected to flourish the demand for precision medicine for effective therapeutic approach.
Based on end-use, pharmaceutical companies dominated the global precision medicine market with prominent revenue share contribution in the year 2019. The growth is mainly attributed to the availability of advanced and innovative techniques including next generation sequencing for identifying the drug related genetic alterations. In addition, major market participants in the precision medicine industry are involved in various investment programs that further escalate the market growth.

Some of the prominent players in the precision medicine market include:

Biocrates Life Sciences
Tepnel Pharma Services
Novartis
Qiagen
Quest Diagnostics
Menarini Silicon Biosystems
NanoString Technologies
Eagle Genomics
Pfizer
Intomics
Roche
Teva Pharmaceutical

Segments Covered in the Report

By Technology

Bioinformatics
Big Data Analytics
Drug Discovery
Gene Sequencing
Companion Diagnostics
Others

By Application

CNS
Immunology
Oncology
Respiratory
Others

By End-Use

Diagnostic Companies
Pharmaceutical Companies
Healthcare IT companies
Others

By Sequencing Technology

Sequencing by Synthesis
Ion Semiconductor Sequencing
Sequencing by Ligation
Pyrosequencing
Single Molecule Real Time Sequencing
Chain Termination Sequencing
Nanopore Sequencing

By Product

Consumables
Instruments
Services

By Route of Administration

Oral
Injectable

By Drugs

Alectinib
Osimertinib
Mepolizumab
Aripiprazole Lauroxil
Others

By Regional Outlook

North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
Asia Pacific
- China
- India
- Japan
- South Korea
Rest of the World

Table of Content

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers

Chapter 7. Global Precision Medicine Market, By Technology

7.1. Precision Medicine Market, by Technology Type, 2021-2030
7.1.1. Bioinformatics
7.1.1.1. Market Revenue and Forecast (2019-2030)
7.1.2. Big Data Analytics
7.1.2.1. Market Revenue and Forecast (2019-2030)
7.1.3. Drug Discovery
7.1.3.1. Market Revenue and Forecast (2019-2030)
7.1.4. Gene Sequencing
7.1.4.1. Market Revenue and Forecast (2019-2030)
7.1.5. Companion Diagnostics
7.1.5.1. Market Revenue and Forecast (2019-2030)
7.1.6. Others
7.1.6.1. Market Revenue and Forecast (2019-2030)

Chapter 8. Global Precision Medicine Market, By Application

8.1. Precision Medicine Market, by Application, 2021-2030
8.1.1. CNS
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Immunology
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Oncology
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Respiratory
8.1.4.1. Market Revenue and Forecast (2019-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Precision Medicine Market, By End-Use

9.1. Precision Medicine Market, by End-Use, 2021-2030
9.1.1. Diagnostic Companies
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Pharmaceutical Companies
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Healthcare IT companies
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Precision Medicine Market, Regional Estimates and Trend Forecast

10.1. North America
10.1.1. Market Revenue and Forecast, by Technology (2019-2030)
10.1.2. Market Revenue and Forecast, by Application (2019-2030)
10.1.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Technology (2019-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.1.4.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Technology (2019-2030)
10.1.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.1.5.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Technology (2019-2030)
10.2.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Technology (2019-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.4.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Technology (2019-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.5.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Technology (2019-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.6.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Technology (2019-2030)
10.2.7.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.7.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Technology (2019-2030)
10.3.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Technology (2019-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.4.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Technology (2019-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.5.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Technology (2019-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.6.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Technology (2019-2030)
10.3.7.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.7.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Technology (2019-2030)
10.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Technology (2019-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.4.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Technology (2019-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.5.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Technology (2019-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.6.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Technology (2019-2030)
10.4.7.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.7.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Technology (2019-2030)
10.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.5.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Technology (2019-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.5.4.3. Market Revenue and Forecast, by End-Use (2019-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Technology (2019-2030)
10.5.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.5.5.3. Market Revenue and Forecast, by End-Use (2019-2030)

Chapter 11. Company Profiles

11.1. Biocrates Life Sciences
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Tepnel Pharma Services
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Novartis
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Qiagen
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Quest Diagnostics
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Menarini Silicon Biosystems
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. NanoString Technologies
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Eagle Genomics
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Pfizer
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Intomics
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. Roche
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. Teva Pharmaceutical
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives